Four bottles and three plastic vial samples of alpha-1-antitrypsin, PPL Therapeutics' first medicinal protein product. Made by genetically modified sheep (Tracy being the first of these) and extracted from their milk at the facility near Edinburgh. At the time of collecting, AAT was in clinical trials as a treatment for the symptoms of cystic fibrosis. Made in 1998.

Alpha-1-antitrypsin is a protein in the body used to protect the lining of the lungs; its absence causes severe lung problems such as emphysema. Genetically engineered Alpha-1-antitrypsin can be used to supplement any deficiency. These samples of the protein were extracted from the milk of sheep genetically modified with human genes by PPL Therapeutics – their first medicinal protein product. In 1998 and 1999, clinical trials of the protein were carried out for its use as a treatment for the symptoms of cystic fibrosis – such as the over production of mucus in the windpipe, which makes breathing difficult and causes severe infections. However, the product was not commercialised.